RIPC and Platelet Activation on Platelet Activation During Cardiopulmonary Bypass
- Conditions
- Platelet Dysfunction
- Interventions
- Device: Remote ischemic preconditioningDevice: Sham control
- Registration Number
- NCT03458351
- Lead Sponsor
- Seoul National University Hospital
- Brief Summary
In this study, the investigators are going to investigate the effects of remote ischemic preconditioning on platelet activation in patients undergoing cardiac surgery with cardiopulmonary bypass.
- Detailed Description
Previous studies reported that remote ischemic conditioning reduce platelet activation in patients with coronary artery disease or patients undergoing ablation for atrial fibrillation. Cardiac surgery with cardiopulmonary bypass has been associated with platelet activation. In this randomized study, investigators are going to compare the effects of remote ischemic preconditioning (RIPC) on platelet activation using flow cytometry in patients undergoing cardiac surgery with cardiopulmonary bypass.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 58
- Patients undergoing cardiac surgery with cardiopulmonary bypass
- Preoperative left ventricle ejection fraction < 30%, mechanical ventricular support
- Peripheral vascular disease
- Poorly controlled diabetes mellitus
- NSAIDs within 3 days
- iv heparin within 6 h
- low molecular weight heparin within 24 h
- platelet inhibitor within 24 h
- known thrombocytopenia
- End stage renal disease / hemodialysis
- Active infection
- Pregnancy
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Remote ischemic preconditioning Remote ischemic preconditioning Remote ischemic conditioning after anesthesia induction - four cycles of 5 min of ischemia followed by 5 min of reperfusion by inflation to 200 mm Hg and deflation of a blood pressure cuff on the upper arm Sham control Sham control The same blood pressure cuff is placed around the upper arm, but the cuff is inflated to 10mm Hg.
- Primary Outcome Measures
Name Time Method Platelet activation measured by CD62P expression using flow cytometry During 3hour after cardiopulmonary bypass initiation CD62P AUC (area under the curve)
- Secondary Outcome Measures
Name Time Method ASPItest by Multiplate® platelet function analyser 3hour after cardiopulmonary bypass initiation ASPItest AU
Platelet activation measured by platelet microparticles (PMP) expression using flow cytometry During 3hour after cardiopulmonary bypass initiation PMP AUC (area under the curve)
ADPtest by Multiplate® platelet function analyser 3hour after cardiopulmonary bypass initiation ADPtest AU
COLtest by Multiplate® platelet function analyser 3hour after cardiopulmonary bypass initiation COLtest AU
Platelet activation measured by CD63 expression using flow cytometry During 3hour after cardiopulmonary bypass initiation CD63 AUC (area under the curve)
Platelet activation measured by monocyte-platelet aggregates (MPA) expression using flow cytometry During 3hour after cardiopulmonary bypass initiation MPA AUC (area under the curve)
Platelet activation measured by PAC1 expression using flow cytometry During 3hour after cardiopulmonary bypass initiation PAC1 AUC (area under the curve)
Trial Locations
- Locations (1)
Seoul National University Hospital
🇰🇷Seoul, Korea, Republic of